Umuthi omusha we-Antidiabetic one-Triple Combination Therapy

A BAMBA MahhalaRelease 3 | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-Daewoong Pharmaceutical imemezele imiphumela ephezulu kakhulu yocwaningo lomtholampilo lwesigaba sesi-3 sokwelashwa okuhlanganisiwe okuphindwe kathathu kwe-Enavogliflozin, umuthi omusha we-antidiabetic osebenza ngendlela ye-SGLT-2 inhibitor, ene-Metformin ne-Gemigliptin. I-Enavogliflozin iyisivimbeli se-SGLT-2 sesifo sikashukela esakhiwa yi-Daewoong okokuqala ngqa eSouth Korea.               

USolwazi Sungrae Kim wase-Catholic University of Korea Isibhedlela i-Bucheon St. Mary's njengomphenyi ongumxhumanisi nabaphenyi abayinhloko abavela ezikhungweni ezingu-27 babambe iqhaza ocwaningweni lomtholampilo lwesigaba 3 se-Enavogliflozin njengendlela yokwelapha eyinhlanganisela kathathu ne-Metformin ne-Gemigliptin. Ucwaningo lwenziwe njengesivivinyo somtholampilo esihlanganisa izikhungo eziningi, esingahleliwe, esiyimpumputhe kabili, futhi esilawulwa ngokusebenzayo esihlanganisa iziguli ezingama-3 ezinesifo sikashukela sohlobo 270.

Iziguli ezinesifo sikashukela sohlobo 2, ezazinikezwe i-metformin ne-Gemigliptin, zaphinde zanikezwa i-Enavogliflozin noma i-Dapagliflozin amasonto angama-24, kanye noshintsho oluyisisekelo lwe-glycated hemoglobin (HbA1c) phakathi kwamaqembu amabili ocwaningo lwaqhathaniswa ngesikhathi sokwelashwa. Ngenxa yalokhu, iziguli ezinikezwe i-Enavogliflozin zibonise ukwehla kwezinga le-HbA1c ngo-0.92% kanye no-0.86% kulawo maphilisi e-Dapagliflozin, ngaleyo ndlela kwafakazela ubuncane be-enavogliflozin uma kuqhathaniswa ne-Dapagliflozin.

Ukuphepha kwe-Enavogliflozin kwabuye kwaqinisekiswa ezigulini ezinesifo sikashukela esimaphakathi, ezidinga ukwelashwa okuhlangene kwe-metformin ne-Gemigliptin, njengoba kwakungekho ukusabela okubi okungalindelekile kwezidakamizwa noma ukusebenzisana kwezidakamizwa. Ukuphepha kwe-Enavogliflozin kufakazelwe ngezivivinyo ezintathu ezilandelanayo zomtholampilo ze-monotherapy, inhlanganisela ye-metformin, nenhlanganisela ye-metformin ne-Gemigliptin.

Umphenyi ongumxhumanisi, uSolwazi Kim uthe, "Ukuhlolwa komtholampilo kwe-Enavogliflozin's triple combination therapy uma kuqhathaniswa ne-Dapagliflozin ezigulini ezingaba ngu-270 zase-Korea T2DM amasonto angu-24 kufakazele ukuphepha kanye nemiphumela evelele yokwehlisa ushukela wegazi we-Enavogliflozin." "Kulindeleke ukuthi i-Enavogliflozin ibe inketho yokwelapha engcono enenkomba ye-monotherapy kanye nokwelashwa okuhlangene," engeza.

Ikhipha imiphumela ezuzisayo evela ocwaningweni lomtholampilo lwesigaba 3 sokwelashwa okuhlanganisiwe okuphindwe kathathu kwe-Enavogliflozin, i-Daewoong manje isiyisinyathelo esiseduze nokukhishwa kwe-SGLT-2 inhibitor okokuqala ngqa e-South Korea. U-Daewoong uhlela ukufaka isicelo ngokushesha sokugunyazwa komuthi omusha futhi angaqalisi ukwethula i-Enavogliflozin kuphela kodwa futhi nenhlanganisela yomthamo ongashintshi we-Enavogliflozin/Metformin engxenyeni yokuqala ka-2023. U-Daewoong ukhiphe imiphumela ephezulu kakhulu yocwaningo lomtholampilo lwesigaba 3 se-Enavogliflozin monotherapy ne-Metformin. Inhlanganisela yokwelapha kulo Januwari.

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...